US Removes Strictest Black Box Warning From Three Estrogen Patches as Menopause Treatment Demand Surges

WASHINGTON — The United States health department on Friday, 30 October 2026, approved the removal of the strictest "black box" warnings from the labels of three estradiol transdermal patches, the hormone therapies used to treat menopause symptoms, Reuters reported. The move extends a sweeping overhaul of menopause hormone therapy labelling that began earlier this year, at a time when demand for estrogen patches is still outpacing supply.

The decision matters for millions of women navigating menopause — and for the doctors and pharmacists trying to help them. Hot flashes, night sweats, mood swings and sleep disturbances can disrupt work, relationships and daily life, and estrogen patches have become one of the most sought-after ways to ease those symptoms. Yet for more than two decades, the strongest warning on the label discouraged many patients and prescribers alike. Friday's action removes that warning from three more patch products, even as pharmacies continue to report difficulty keeping them in stock.

This article reports regulatory and supply news. It is general information, not medical advice, and anyone considering hormone therapy should discuss benefits and risks with their own clinician.

Illustration: A pharmacist handing an estrogen patch box to a woman at a pharmacy counter. This is an AI-generated illustration, not a real photograph.

What Happened

Reuters reported on Friday that the US Department of Health and Human Services (HHS) had approved removing the broad black box warnings from three estradiol transdermal patches. A black box warning — now more commonly called a boxed warning — is the most prominent safety warning the US Food and Drug Administration (FDA) can require on a medicine's label.

Reuters said HHS did not immediately respond to its request seeking the brand names of the three patches covered by the latest action. That detail matters for patients checking their own prescriptions, and it had not been disclosed in the Reuters report at the time of publication. What is clear is the direction of travel: the latest approvals add to a series of labelling changes approved by the FDA in February 2026, which removed warnings related to cardiovascular disease, breast cancer and probable dementia from six menopausal hormone therapy products.

Friday's announcement also arrived alongside a supply update. Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, said on a media call that estrogen patch market output had doubled over the past year and that manufacturers continue to expand capacity, according to Reuters. Sarah Ibrahim, deputy center director for regulatory programs at the FDA's Center for Drug Evaluation and Research, said the FDA had expedited the review and approval of 10 supplements this year to date — requests from manufacturers to make changes that could expand production — and that two of those requests were approved within the past week alone.

The FDA has been working with manufacturers since September to boost supplies of estrogen patches, Reuters reported, but it has not designated the patches as being in shortage. That distinction has become a point of contention: while the agency says supply has grown sharply, many patients still report struggling to fill prescriptions, and some injectable and vaginal estrogen products have also been reported in short supply.

Background

To understand why a label change can move a whole market, it helps to go back to 2002. That year, the Women's Health Initiative (WHI), a large US study, announced findings linking hormone therapy to increased risks of breast cancer, heart disease and other serious conditions in postmenopausal women. Use of hormone therapy fell sharply in the years that followed, and the boxed warnings that followed the study stayed on labels for more than two decades.

Over time, researchers and regulators re-examined that evidence and concluded that the original warnings had been applied more broadly than the data justified. In particular, later analyses suggested that the balance of benefits and risks looks most favourable when therapy begins before age 60 or within 10 years of the onset of menopause — a nuance that a blanket warning did not capture. The Menopause Society's 2022 position statement reached a similar conclusion for most healthy, symptomatic women in that group, stating that benefits generally outweigh risks.

The regulatory turning point came in stages. In July 2025, the FDA convened an expert panel on menopause and hormone therapy. On 10 November 2025, HHS and the FDA announced they would remove the boxed warnings on menopausal hormone therapy products, following a comprehensive review of the science. On 12 February 2026, the FDA formally approved labelling changes for the first six products, removing the boxed-warning statements about cardiovascular disease, breast cancer and probable dementia.

Crucially, the February overhaul did not remove every warning. Risks still appear in the labels' warnings and precautions sections, and the boxed warning about endometrial cancer remains on systemic estrogen-alone products for women who still have a uterus — which is why women with a uterus are generally prescribed a progestogen alongside systemic estrogen. Friday's action for three patches should be read in that same light: it removes the broadest warning, not the need for careful, individualised prescribing.

Illustration: A health agency building with a magnifying glass over a medicine label document. This is an AI-generated illustration, not a real photograph.

Why It Matters

First, labelling shapes behaviour. A black box warning is designed to be unmissable, and for years it signalled to many women — and to some clinicians — that hormone therapy was unusually dangerous. Removing it from more products does not declare hormone therapy risk-free, but it does bring the label closer to how regulators now read the evidence, and it may reduce the fear that has kept some symptomatic women from seeking treatment at all.

Second, the timing exposes a supply problem that labelling alone cannot fix. Reuters reported on 28 October 2026 that women struggling to find hormone replacement treatments were facing shortages beyond estrogen patches, with some injectable and vaginal estrogen products also in short supply. Demand for hormone therapy has increased following the removal of the long-standing boxed warning, and some women switching from hard-to-find patches to alternatives may partly explain the widening crunch, according to Kevin Schipper, director of product lifecycle management at pharmaceutical consulting firm ProPharma, cited by Reuters.

The numbers behind the crunch are striking. The FDA said in September that the US supply of FDA-approved estradiol patches had nearly doubled over the previous year but had not kept up with demand. Viatris, one of several manufacturers of estradiol patches and creams, said it had seen a "significant surge in demand" and had been working throughout the year to increase supply, while Amneal, another patch manufacturer, said demand had increased significantly following the warning removal and that it was working to increase production, Reuters reported.

Pharmacy monitors tell a similar story. The American Society of Health-System Pharmacists listed multiple estradiol injection products from Hikma, American Regent and Par Sterile Products as being in shortage in early September, and separately listed vaginal estradiol creams made by Viatris' Mylan unit, Padagis and Teva as being on backorder or allocation, Reuters reported on 28 October. For patients, that means a prescription change is not always a simple swap: a different form, strength or brand may also be hard to find, or may not suit them.

Third, the issue has reached lawmakers. Reuters and other US outlets have reported that senators, including Kirsten Gillibrand of New York, pressed the FDA in October to share a plan to make estrogen patches available, including emergency measures. The FDA's position, as reported by Reuters on Friday, is that it is working expeditiously with applicants on labelling changes for the remaining menopausal hormone therapy products — a signal that more label updates, not just more patches, are still to come.

What Happens Next

In the short term, patients and prescribers will be watching for two things: which three patches are covered, once brand names are confirmed, and whether the updated labels reach pharmacies quickly enough to change conversations at the counter. The FDA said it is working expeditiously on labelling changes for the remaining products, so further approvals in the same series are likely.

On supply, the question is whether expanded manufacturing capacity can catch up with demand that is still rising. Patch output has doubled in a year, according to the health department, and 10 manufacturing supplements have been expedited this year — but patches require specialised equipment and careful quality control, and building new capacity takes time. Until supply steadies, pharmacists, prescribers and patients may need to keep discussing alternatives such as gels, sprays or other formulations, and to check availability pharmacy by pharmacy.

Longer term, Friday's decision is likely to be judged alongside the February overhaul as a single chapter: the end of a warning regime shaped by a 2002 study, replaced by labels that try to reflect age, timing and individual risk more precisely. Whether that shift translates into better, more equitable access — rather than simply more demand chasing the same constrained supply — will depend on manufacturing, prescribing guidance and, above all, whether women who need treatment can actually get it.

Illustration: A doctor discussing treatment options with a woman in a clinic consultation room. This is an AI-generated illustration, not a real photograph.

Sponsored: explore today's featured sponsored offers

FAQ

What did the US health department approve on 30 October 2026?

It approved removing the strictest black box warnings from the labels of three estradiol transdermal patches used to treat menopause symptoms, Reuters reported on Friday. The brand names were not immediately disclosed in the Reuters report.

Is this the first time such warnings have been removed?

No. The FDA approved labelling changes in February 2026 removing warnings related to cardiovascular disease, breast cancer and probable dementia from six menopausal hormone therapy products, following an announcement in November 2025. Friday's action extends that overhaul to three more patch products.

Does removing the black box warning mean hormone therapy is safe for everyone?

No. Other risks still appear in the labels' warnings and precautions, and the boxed warning about endometrial cancer remains on systemic estrogen-alone products. Benefits and risks vary by age, timing, medical history and other factors, which is why treatment decisions should be made with a clinician.

Why are estrogen patches hard to find?

Demand has surged since the boxed warnings began to be removed, while patch manufacturing capacity has expanded more slowly. The FDA said patch supply had nearly doubled over the past year but had not kept up with demand, and Reuters reported on 28 October that some injectable and vaginal estrogen products were also in short supply.

What happens next?

The FDA said it is working expeditiously on labelling changes for the remaining menopausal hormone therapy products, and manufacturers are expanding capacity. Patients should watch for confirmation of the three patch brands covered and check availability with their pharmacy and prescriber.

Sources

Reuters, "US health department to remove broad black box warning from three estrogen patch products," 30 October 2026; Reuters, "US estrogen supply crunch widens as women seek alternatives to scarce patches," 28 October 2026; FDA, "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products," 12 February 2026, as summarised by Cancer Network and the FDA.